ImmunityBio, Inc.

To our Veterans: Thank you for your service.

As we honor you today, we recognize the impact of bladder cancer on the Veteran community. According to a new ImmunityBio survey conducted by @HarrisPoll, 53% of Veterans and military service members with NMIBC were diagnosed by age 50, including 28% by age 40.

Throughout November, we’ll be sharing what Veterans told us about navigating NMIBC to bring greater awareness to their experiences and needs.

Learn more about what Veterans shared: immunitybio.com/new-u-s-survey…

ImmunityBio shared three announcements today:

· QUILT-2.005: ANKTIVA® plus BCG met the primary endpoint in Cohort A of the randomized BCG-naïve, high-grade NMIBC trial
· Israel Approval: ANKTIVA® plus BCG was approved for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors
· Q3 2026 & Global Progress: Net product revenue reached $48.7 million, up 53% year over year, alongside U.S. label expansion and an additional global approval

Read the full releases for complete information and important disclosures:
immunitybio.com/news-and-event…

Each November, #LungCancerAwarenessMonth highlights the importance of education, early detection, and innovation.

ImmunityBio is proud to support this awareness by researching new approaches for patients with lung cancer, where significant unmet need remains.

ImmunityBio is heading to #LUGPA2026.

We look forward to learning, connecting, and celebrating the strength of independent urology with practice leaders and clinicians.

Visit us at booth #712 to connect with our team.

We're thrilled to share a major milestone: the first patients in Europe have been treated with ANKTIVA® + BCG for BCG-unresponsive NMIBC with CIS, beginning in Germany & Austria, following the EC's February 2026 conditional authorization.

With support from partners Accord Healthcare and Uniphar, we're working to expand access for eligible patients across Europe.

Full press release & Important Safety Information: immunitybio.com/immunitybio-an…